Description
Anti-Ebola virus glycoprotein Antibody, ADCC Enchanced (BioBet-CB-049LX) is a glycosylation-modified anti-Ebola virus glycoprotein therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Ebola virus glycoprotein antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Ebola virus glycoprotein
Full Name
Ebola virus glycoprotein
Background
Ebola is a serious and deadly virus transmitted by animals and humans. It was initially detected in 1976 in Sudan and the Democratic Republic of Congo. The Ebola virus belongs to the viral family Filoviridae. Scientists also call it Filovirus.
Alternative Names
Ebola virus glycoprotein; GP; EBLV;
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-049LX
Description
ADCC-Enhanced Anti-Human Ebola virus glycoprotein (mAb114) Antibody is derived from clone mAb114, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the Ebola virus glycoprotein, and it is intended for the research of Ebola virus infection.
Antibody Indication
Ebola virus infection
